B+
Bull case
15%
Probability
Target price
$0.85
+224.9% vs current
ENSC
Ensysce BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexB
Base case
40%
Probability
Target price
$0.18
-31.2% vs current
Most likely
B-
Bear case
45%
Probability
Target price
$0.05
-80.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-30
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+33.4
Score
AI commentary
Primary-source tone turned more negative after the May 22 8-K because listing compliance is now an immediate process with a July 6 plan deadline, while the May 15 10-Q confirms very limited cash and ongoing dilution risk. Coverage is still thin, there is no usable analyst-revision or social-context signal, and the stock remains a binary microcap tied to funding and clinical timing rather than durable fundamentals.
RankAlpha Sentiment Codex - 2026-05-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-06catalystNasdaq equity shortfall enters a formal plan windowHigh impact
On May 21, 2026 Nasdaq notified ENSC that it was below the $2.5 million stockholders' equity requirement; the company must submit a compliance plan by July 6, 2026, and rejection of that plan or failure to regain compliance would keep delisting risk front and center [#8-K-2026-05-22].
2026-08-31eventPF614-301 enrollment is still the main clinical upside hookHigh impact
PF614-301 remains the main asset-level upside hook: the 10-K says the pivotal Phase 3 trial started in July 2025 and enrollment began in December 2025, so any enrollment update or interim-development milestone over the next few months could drive a sharp re-rating [#10-K-2026-03-30].
2026-09-30catalystCash runway remains tight and financing likelyHigh impact
Runway and dilution remain the structural long-term issue: the 10-Q shows cash and cash equivalents fell to $745,482 at March 31, 2026 from $4.31 million at year-end 2025, says cash funds operations only into late Q2 2026, and warns future viability depends on additional capital [#10-Q-2026-05-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-30 • Updated nightlySource: Internal modelMethodology